These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3273250)

  • 1. [Beta-Curie contact therapy in the conservative treatment of uveal melanoma. Evaluation of the first 100 cases treated].
    Grange JD
    Bull Soc Belge Ophtalmol; 1988; 229():15-21. PubMed ID: 3273250
    [No Abstract]   [Full Text] [Related]  

  • 2. [Report on 50 cases of uveal melanoma treated by conservative beta curietherapy].
    Grange JD; Bonnet M; Bievelez B; Jean-Louis B; Quintero P; Santamaria E; Guillaubey Y; Gérard JP; Delaroche G; Mere P
    Bull Soc Ophtalmol Fr; 1987 Nov; 87(11):1297-300. PubMed ID: 3451841
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruthenium applicators in the treatment of choroidal melanomas.
    Van Hijfte R; Verbraeken H; De Laey JJ
    Bull Soc Belge Ophtalmol; 1987; 224():51-8. PubMed ID: 3509023
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible effects of radiobiological parameters on metastatic spread of uveal melanomas treated with 106Ru plaques.
    Kleineidam M; Guthoff R
    Ger J Ophthalmol; 1994 Jan; 3(1):22-5; discussion 25-6. PubMed ID: 8142877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of ciliary body melanoma by beta radiation.
    Foerster MH; Wessing A; Meyer-Schwickerath G
    Trans Ophthalmol Soc U K (1962); 1983; 103 ( Pt 1)():64-7. PubMed ID: 6581638
    [No Abstract]   [Full Text] [Related]  

  • 6. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
    Razzaq L; de Keizer RJ
    Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
    [No Abstract]   [Full Text] [Related]  

  • 7. [The potential for organ-preserving treatment in large uveal melanoma].
    Terent'eva LS; Fokin VP
    Oftalmol Zh; 1989; (6):338-41. PubMed ID: 2622597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
    Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
    Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
    Toivonen P; Kivelä T
    Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome.
    Fili M; Lundell G; Lundell M; Seregard S
    Br J Ophthalmol; 2014 Oct; 98(10):1349-54. PubMed ID: 24825846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined radiotherapy of uveal melanoma].
    Brovkina AF; Kesheleva VV; Fridman FE; Fishkin IG
    Vestn Oftalmol; 1997; 113(2):10-2. PubMed ID: 9229894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
    Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
    Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
    Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impression cytology of the conjunctiva following high-dose brachytherapy of malignant melanoma of the uvea using 106Ru/106Rh applicators].
    Koch JM; Bornfeld N; Waubke TN; Wessing A
    Fortschr Ophthalmol; 1988; 85(6):642-5. PubMed ID: 3220378
    [No Abstract]   [Full Text] [Related]  

  • 15. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
    Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
    Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retina dose as a predictor for visual acuity loss in
    Heilemann G; Fetty L; Blaickner M; Nesvacil N; Zehetmayer M; Georg D; Dunavoelgyi R
    Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Criteria for assessing the efficacy of brachytherapy of uveal melanomas, complications of therapy and there prevention].
    Brovkina AF; Zarubeí GD; Val'skií VV
    Vestn Oftalmol; 1997; 113(3):14-6. PubMed ID: 9265351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981-1989.
    Pötter R; Janssen K; Prott FJ; Widder J; Haverkamp U; Busse H; Müller RP
    Front Radiat Ther Oncol; 1997; 30():143-9. PubMed ID: 9205894
    [No Abstract]   [Full Text] [Related]  

  • 19. Panophthalmitis with acute scleral necrosis after brachytherapy of a malignant melanoma of the ciliary body.
    Bodanowitz S; Strempel I; Wiegand W; Kroll P
    Ger J Ophthalmol; 1995 Nov; 4(6):380-2. PubMed ID: 8751105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plexiglass replicas for optimizing selection and site of ruthenium 106 applicators].
    Menapace R
    Klin Monbl Augenheilkd; 1990 Jan; 196(1):40-2. PubMed ID: 2313993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.